MRNS:NSD-Marinus Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.15

Change

+0.45 (+4.21)%

Market Cap

USD 1.47B

Volume

2.32M

Average Target Price

USD 9.75 (-12.56%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+5.05 (+1.92%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+16.60 (+2.98%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+5.52 (+3.08%)

USD31.19B N/A N/A
MRNA Moderna, Inc

+4.30 (+6.60%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-0.16 (-0.40%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

+2.41 (+2.15%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+5.83 (+2.11%)

USD24.64B N/A N/A
GMAB Genmab A/S

+1.03 (+2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.06 (+0.07%)

USD19.69B N/A N/A
INCY Incyte Corporation

+1.48 (+1.74%)

USD18.80B 47.64 35.20

ETFs Containing MRNS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.05% 72% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.05% 72% C- 81% B-
Trailing 12 Months  
Capital Gain 83.39% 77% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.39% 77% C+ 88% B+
Trailing 5 Years  
Capital Gain -77.06% 31% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.06% 31% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 60.68% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.68% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 198.35% N/A N/A N/A N/A
Risk Adjusted Return 30.59% N/A N/A N/A N/A
Market Capitalization 1.47B 82% B- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.25 51% F 31% F
Price / Cash Flow Ratio -30.18 87% B+ 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -86.05% 37% F 15% F
Return on Invested Capital -85.10% 32% F 11% F
Return on Assets -45.54% 21% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.34 34% F 21% F
Short Percent 12.14% 25% F 18% F
Beta 1.99 26% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector